(Q37328423)

19 August 2017

Serum biomarkers for early detection of gynecologic cancers (English)

1 reference

19 August 2017

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281117%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

4

Takashi Miyatake

1 reference

9 June 2020

7

Tadashi Kimura

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281117%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

2

Takayuki Enomoto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281117%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1

Yutaka Ueda

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281117%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

3

Toshihiro Kimura

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281117%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

6

Masami Fujita

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281117%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

publication date

14 June 2010

1 reference

19 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281117%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281117%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281117%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

1312-1327

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281117%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

9 June 2020

copyright license

start time

14 June 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Serum amyloid A: a novel biomarker for endometrial cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

A strategy for discovery of cancer glyco-biomarkers in serum using newly developed technologies for glycoproteomics.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Identification of potential serum markers for endometrial cancer using protein expression profiling

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

HE4 as a biomarker for ovarian and endometrial cancer management

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Validation of candidate serum ovarian cancer biomarkers for early detection

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Clinical practice. Screening for ovarian cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Serum proteomic features for detection of endometrial cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Early ovarian cancer: 3-D power Doppler

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Serum tumor markers in the management of ovarian, endometrial and cervical cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Specific keynote: ovarian cancer risk assessment and the potential for early detection

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Clinical value of thymidine kinase in patients with cervical carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Serum soluble fas level as a prognostic factor in patients with gynecological malignancies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Serum and tissue measurements of CA72-4 in patients with endometrial carcinoma.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

The CA 125 tumour-associated antigen: a review of the literature

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Radiation-induced CA 125 production by mesothelial cells

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Tumor markers CA 125, carcinoembryonic antigen and tumor-associated trypsin inhibitor in patients with cervical adenocarcinoma

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Validation of serum biomarkers for detection of early-stage ovarian cancer.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Serum YKL-40 as a marker for cervical adenocarcinoma.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Evaluation of serum amyloid A as a biomarker for gastric cancer.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Comparison of pre-treatment CYFRA 21 - 1 and SCC-Antigen assay in primary cervical carcinoma - a preliminary report.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A [corrected].

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Assessment of cervical cancer radioresponse by serum squamous cell carcinoma antigen and magnetic resonance imaging.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Serum vascular endothelial growth factor and serum leptin in patients with cervical cancer.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Improvement of clinical staging in cervical cancer with serum squamous cell carcinoma antigen and CA 125 determinations.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835131

Multiple tumour marker assays in advanced cervical cancer: relationship to chemotherapy response and clinical outcome

2 September 2018

1 reference

12 December 2020

The prognostic value of TPA and SCC in squamous cell carcinoma of the cervix

1 reference

12 December 2020

Immunosuppressive acidic protein in patients with gynecologic cancer

1 reference

12 December 2020

Serum and tissue measurements of CA72-4 in ovarian cancer patients

1 reference

12 December 2020

TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer

1 reference

12 December 2020

Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix

1 reference

12 December 2020

Preoperative serum SCC, CA125, and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix

1 reference

12 December 2020

Comparison between squamous cell carcinoma-associated antigen and CA-125 in patients with carcinoma of the cervix

1 reference

12 December 2020

Clinical use of CA 125 and its combination assay with other tumor marker in patients with ovarian carcinoma

1 reference

12 December 2020

Prognostic significance of tumour markers in endometrial cancer

1 reference

12 December 2020

Validation of serum biomarkers for detection of early- and late-stage endometrial cancer

1 reference

12 December 2020

The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma

1 reference

12 December 2020

The value of tumour marker CA 125 in surgical pathology

1 reference

12 December 2020

Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?

1 reference

12 December 2020

Multiple serum markers in patients with endometrial cancer

1 reference

12 December 2020

Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies

1 reference

12 December 2020

The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis

1 reference

12 December 2020

Combined use of CA 125 and CA 15-3 in patients with endometrial carcinoma

1 reference

12 December 2020

Diagnostic markers for early detection of ovarian cancer

1 reference

12 December 2020

Tissue and serum CA125 expression in endometrial cancer

1 reference

12 December 2020

Tumour markers and their prognostic value in adenocarcinoma of the cervix

1 reference

12 December 2020

Immunosuppressive acidic protein and CA 125 levels in patients with ovarian cancer

1 reference

12 December 2020

Squamous cell carcinoma antigen, tumor-associated trypsin inhibitor, and carcinoembryonic antigen for monitoring cervical cancer

1 reference

12 December 2020

Urinary gonadotropin fragment, a new tumor marker. III. Use in cervical and vulvar cancers

1 reference

12 December 2020

Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA125 and CA15.3 serum assays

1 reference

12 December 2020

Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix

1 reference

12 December 2020

Macrophage colony-stimulating factor 1, a clinically useful tumor marker in endometrial adenocarcinoma: Comparison with CA 125 and the aminoterminal propeptide of type III procollagen

1 reference

12 December 2020

Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers

1 reference

12 December 2020

Immunosuppressive acidic protein in patients with ovarian cancer

1 reference

12 December 2020

Immunosuppressive acidic protein (IAP) and squamous cell carcinoma antigen (SCC) in patients with cervical cancer

1 reference

12 December 2020

A comparison of pretreatment serum levels of four tumor markers in patients with endometrial and cervical carcinoma

1 reference

12 December 2020

Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma

1 reference

12 December 2020

The clinical value of squamous cell carcinoma antigen in cancer of the uterine cervix

1 reference

12 December 2020

Combined assay of serum levels of CA125 and CA19-9 in endometrial carcinoma

1 reference

12 December 2020

ACOG Practice Bulletin no. 109: Cervical cytology screening

1 reference

12 December 2020

The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer

1 reference

12 December 2020

Immunosuppressive acidic protein (IAP) and CA 125 assays in detection of human ovarian cancer: preliminary results

1 reference

12 December 2020

Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer

1 reference

12 December 2020

Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer

1 reference

12 December 2020

Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer?

1 reference

12 December 2020

Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer

1 reference

12 December 2020

Serum CYFRA 21-1 in cervical cancer patients treated with radiation therapy

1 reference

12 December 2020

Identifiers

DOI

10.3390/CANCERS2021312

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281117%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281117%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

PubMed publication ID

24281117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281117%20AND%20SRC:MED&resulttype=core&format=json